RecruitingNot Applicable

Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease

China3,100 participantsStarted 2025-02-28

Plain-language summary

The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target achievement rate compared to a traditional management strategy without follow-up CCTA, thereby reducing the incidence of major adverse cardiovascular and cerebrovascular events over a 3 years period, including all-cause mortality, myocardial infarction, ischemia driven revascularation and stroke.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age between 18 and 80 years old;
✓. Known patients with non-obstructive coronary artery disease (disease duration ≥2 years);
✓. Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations.

Exclusion criteria

✕. Patients who have experienced ACS or PCI/CABG;
✕. Patients who have experienced adverse cardiovascular and cerebrovascular events;
✕. Patients who have undergone follow-up CCTA or DSA examinations before enrollment;
✕. Patients with severe hepatic and renal dysfunction;
✕. Patients with contraindications to CCTA examinations;
✕. Patients with poor initial CCTA image quality or data loss.

What they're measuring

Major adverse cardiovascular and cerebrovascular event

Timeframe: 36 months after baseline

Trial details

NCT IDNCT06843005

SponsorZhang longjiang,MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-12-30

Contact for this trial

Longjiang Zhang, MD

13405833167 kevinzhlj@163.com

View on ClinicalTrials.gov More Major Adverse Cardiovascular Events (MACE) trials